NewsBenzingaInflaRx、経口投与可能な次世代低分子C5a受容体阻害薬イジコパンのヒト初回第1相臨床データの査読付き論文掲載を発表 InflaRx、経口投与可能な次世代低分子C5a受容体阻害薬イジコパンのヒト初回第1相臨床データの査読付き論文掲載を発表 Benzinga 2026.11.06 12:32 (GMT+0) Open on Benzinga Other news Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds